Regeneron Pharmaceuticals notified investors today that its longtime partner Sanofi is moving to snap up a big chunk of its stock.
The Thousand Oaks, CA-based biotech powerhouse made an unexpected move in December to buy the pioneering genomics company deCODE for $415 million. Today R&D chief Dr. Sean Harper further explained how the capabilities of the company fit within the broader strategy at Amgen to be more discerning about which research programs to pursue.
The Medicines Co. has bought into one of the most exciting cardio drug targets in biotech, licensing a PCSK9 candidate from Alnylam Pharmaceuticals for $25 million upfront and up to $180 million in milestones, the companies said today.
Those hot PCSK9 bad cholesterol drugs elbowed their way to center ring at the American Heart Association meeting, with Amgen grabbing the spotlight with a fresh batch of positive midstage data on their program for AMG 145.
The monoclonal antibody , AMG-145, has the potential to deliver the biotech giant a blockbuster hit if the compound can continue to generate positive results in clinical trials. Yet the company is seeking the spotlight on a crowded stage of similar drugs in development from Big Pharma rivals.
In the wrap-up of the European Society of Cardiology meeting in Munich, Reuters ' Ben Hirschler assessed the field in search of the next potential Lipitors in the pipeline--megablockbusters that will cost hundreds of millions of dollars to test in huge clinical trials--and came up with three big fields. Each of them has big caveats to consider.
Get ready to see one of hottest areas of cholesterol drug research explode with new studies. Sanofi and partner Regeneron have begun enrollment for late-stage trials to test their drug REGN727 that targets the PCSK9 gene to lower cholesterol. And Roche is fast on their tail with its own Phase III program for a PCSK9 treatment.
As Zerhouni tells the story, Sanofi is essentially starting over on the R&D side, picking up the pieces on the translational side of research; figuring out how to take something truly innovative in the lab and turn it into a new product.
Over the long Memorial Day, weekend Regeneron Pharmaceuticals ($REGN) and Sanofi ($SNY) added to their stockpile of promising mid-stage data for their PCSK9 drug, which is designed to slash levels of "bad" LDL-cholesterol.
The data show that the small company has a horse in the race to advance PCSK9-targeting drugs as a brand new category of treatments for lowering LDL cholesterol.